Loading...
Date of Award
Spring 2020
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Michael Huber
Abstract
Obsessive Compulsive Disorder (OCD) is an anxiety disorder characterized by the recurrence of unwanted thoughts, images or impulses (obsessions) and the resulting repetitive behaviors an individual performs in order to ease their distress (compulsions). Standard first-line medical therapy is with a class of medications known as Selective Serotonin Re-uptake Inhibitors (SSRIs). Approximately one third of patients are refractory to current treatment methods. As a result, this meta-analysis evaluates if, in adults (18+) diagnosed with Obsessive Compulsive Disorder [P], is the addition of pharmacologic drugs targeting Glutamate receptors to current therapy guidelines [I], more effective in relieving symptoms [O] than that of first line treatment with SSRIs alone.
Recommended Citation
Byrnes, Adam, "Efficacy of Pharmacologic Drugs Targeting Glutamate Receptors in Patients Diagnosed with Obsessive Compulsive Disorder Refractory to first line Treatment with SSRI’s" (2020). Capstone Showcase. 20.
https://scholarworks.arcadia.edu/showcase/2020/pa/20
Efficacy of Pharmacologic Drugs Targeting Glutamate Receptors in Patients Diagnosed with Obsessive Compulsive Disorder Refractory to first line Treatment with SSRI’s
Obsessive Compulsive Disorder (OCD) is an anxiety disorder characterized by the recurrence of unwanted thoughts, images or impulses (obsessions) and the resulting repetitive behaviors an individual performs in order to ease their distress (compulsions). Standard first-line medical therapy is with a class of medications known as Selective Serotonin Re-uptake Inhibitors (SSRIs). Approximately one third of patients are refractory to current treatment methods. As a result, this meta-analysis evaluates if, in adults (18+) diagnosed with Obsessive Compulsive Disorder [P], is the addition of pharmacologic drugs targeting Glutamate receptors to current therapy guidelines [I], more effective in relieving symptoms [O] than that of first line treatment with SSRIs alone.